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IMPAIRED MITOCHONDRIAL ACTIVITY IN INSULIN RESISTANT OFFSPRING OF TYPE 2 
DIABETICS. Rina L. Garcia, Sylvie Dufour, Douglas Befroy, Gerald I. Shulman, and Kitt Falk Petersen. 
Section of Endocrinology, Department of Internal Medicine, Howard Hughes Medical Institute, Yale 
University School of Medicine, New Haven, CT. 
The current study was undertaken to examine the mechanism of insulin resistance in healthy, 
young lean insulin resistant offspring of type 2 diabetics compared to age-height-weight-activity matched 
insulin sensitive control subjects. 
Insulin sensitivity of liver and muscle glucose and lipid metabolism were assessed using the 
euglycemic-hyperinsulinemic clamp, in combination with infusions of [6,6-:H2] glucose and [2H5]glycerol. 
’H magnetic resonance spectroscopy studies were performed to assess intramyocellular lipid and 
intrahepatic triglyceride content. Local lipolysis was assessed by measuring glycerol release from 
subcutaneous fat. 31P magnetic resonance spectroscopy was performed in vivo to assess rates of ATP 
synthesis (mitochondrial phosphorylation activity) in the soleus muscle. 
Insulin stimulated muscle glucose uptake was approximately 60 percent lower (P<0.001 versus 
control) in the insulin resistant offspring than in the insulin sensitive control subjects and was associated 
with an approximately 80 percent increase in intramyocellular lipid content (P=0.005 versus control). This 
increase in intramyocellular lipid content is most likely attributable to mitochondrial dysfunction as 
reflected by an approximately 30 percent reduction in mitochondrial phosphorylation activity (P=0.01 
versus control) since there were no differences in systemic or localized rates of lipolysis or plasma 
concentrations of tumor necrosis factor-a, interleukin-6, resistin, or adiponectin. 
These data support the hypothesis that insulin resistance in skeletal muscle of insulin resistant 
offspring is associated with dysregulation of intramyocellular fatty acid metabolism, possibly due to an 
inherited defect in mitochondrial oxidative-phosphorylation activity. 
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Type 2 diabetes mellitus is reaching epidemic proportions worldwide (1) and in 
the United States alone there are more than 16 million people living with the disease (2). 
Although the primary cause of this disease is unknown insulin resistance plays a major 
role in its development. Insulin resistance is defined as impaired glucose uptake by the 
muscle. In the progression to diabetes, there is increased glucose production by the liver 
and an impaired ability of insulin to suppress glucose production. Diabetes develops 
when there is impaired insulin secretion by the pancreas. 
Cross-sectional studies have shown that insulin resistance is present in almost all 
patients with type 2 diabetes and prospective studies have demonstrated that insulin 
resistance is the best predictor for an increased risk of developing type 2 diabetes and is 
often present one to two decades before the onset of the disease (3-5). Furthermore, 
insulin resistance has been shown to be the best predictor for the later development of the 
disease (6) in the offspring of parents with type 2 diabetes. In light of this evidence, our 
focus is to examine the mechanism(s) of insulin resistance in healthy, young, lean 
individuals whose only confounding risk factor for the development of type 2 diabetes is 
having (a) type 2 diabetic parent(s). 
The factors responsible for insulin resistance are not currently well understood. 
There is an excellent correlation between plasma non-esterified (free) fatty acid 
concentrations and insulin sensitivity and more recent studies measuring triglyceride 
content in muscle biopsies (7) or in vivo intramyocellular lipid content by 'H magnetic 
resonance spectroscopy (MRS) (8-11) have a shown a strong relationship between 
intramuscular lipid content and insulin resistance in skeletal muscle in insulin resistant 
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offspring of patients with type 2 diabetes. This suggests that dysregulation of fatty acid 
metabolism may be responsible for mediating the insulin resistance in these individuals. 
In addition, studies have shown that insulin resistance in normoglycemic insulin 
resistant offspring of type 2 diabetics and in type 2 diabetic subjects is secondary to a 
defect in insulin-stimulated glucose transport. The postulated mechanism leading to this 
defect is that increased intramyocellular concentrations of fatty acid metabolites (esp. 
diacylglycerol, fatty acyl coA) secondary to their increased delivery or decreased 
intracellular metabolism activate a serine/threonine kinase cascade. This leads to the 
phosphorylation of serine/threonine sites on insulin receptor substrate-1 and insulin 
receptor substrate-2, which in turn leads to a decreased ability of these insulin receptor 
substrates to activate phosphatidylinositol 3-kinase (12-16) (Figure 1). This in turn leads 
to a decrease in glucose transport activity (17) and a subsequent decrease in glycogen 
synthesis (18, 19), as well as a decrease in other events occurring downstream of the 
insulin signaling cascade. 
In the current study we examined the mechanism responsible for the accumulation 
of intramyocellular lipid in young, lean insulin resistant offspring of type 2 diabetic 
patients. These subjects are ideal for the study of the earliest defects in the pathogenesis 
of type 2 diabetes as they are young, lean, healthy and are less likely to have any of the 
confounding factors present in patients with the disease (e.g., hyperglycemia) that can 
cause insulin resistance per se. We hypothesized that intramyocellular lipid accumulation 
could result from: 1) the increased delivery of lipids from adipocytes secondary to 
increased basal lipolysis and/or decreased insulin-stimulated suppression of lipolysis 
and/or 2) decreased rates of mitochondrial oxidative-phosphorylation activity. We 
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therefore studied these processes in insulin resistant offspring of type 2 diabetic patients 
and in insulin sensitive control subjects. 
Figure 1. Proposed mechanism of insulin resistance in normoglycemic insulin 
resistant offspring of type 2 diabetics and in type 2 diabetic subjects. PKC0, protein 
kinase C0; IRS-1 and IRS-2, insulin receptor substrates; PI 3-kinase, 
phosphatidylinositol 3-kinase. Adopted from (16). 
Rates of whole body and subcutaneous fat lipolysis were assessed by measuring 
*> 
rates of whole body [~H5]glycerol turnover in combination with microdialysis 
measurements of glycerol release from subcutaneous fat. Rates of in vivo mitochondrial 
phosphorylation activity and the ratio of inorganic phosphate to phosphocreatine (P,/Pcr) 
[as an indicator of the relative ratio of type I (mostly oxidative) to type II (mostly 
glycolytic) muscle fiber types] were assessed in skeletal muscle using ' PMRS. This was 
done in order to examine whether the ratio of these fibers could account for potential 
differences in the rates of mitochondrial phosphorylation between the two study groups. 
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Furthermore, the plasma concentrations of tumor necrosis factor- a (TNF-a), interleukin- 
6 (IL-6), resistin and adiponectin were measured in the insulin resistant offspring since 




STATEMENT OF PURPOSE 
The overall aim of this study was to examine the mechanism responsible for the 
accumulation of intramyocellular lipid in young, lean, sedentary, insulin resistant 
offspring of type 2 diabetic patients. Our first specific aim was to study localized and 
whole-body lipolysis to examine the hypothesis that intramyocellular lipid accumulation 
in the insulin resistant offspring results from the increased delivery of lipids from 
adipocytes secondary to increased basal lipolysis and/or decreased insulin-stimulated 
suppression of lipolysis. Our second specific aim was to study rates of mitochondrial 
oxidative phosphorylation in skeletal muscle to examine the hypothesis that 
intramyocellular lipid content in the insulin resistant offspring results from decreased 




Subjects: All subjects were recruited by local advertising over a two year period 
and were prescreened to be healthy, 18-46 years old, lean (BMI<26 kg/m2), non-smoking 
and had a birth weight above 5 pounds. All selected subjects were also sedentary, did not 
exercise regularly and had an Activity Index of less than 3.3, which was calculated using 
an activity index questionnaire (24). Family history of diabetes was obtained through a 
family tree that highlighted relatives with type 2 diabetes. The qualifying subjects, 
approximately 200, were subsequently screened with a standard 75gram [oral glucose 
load], 3-hour oral glucose tolerance test (OGTT). The subjects were then grouped such 
that extreme phenotypes for insulin resistance and increased insulin sensitivity were 
identified. This was determined from the calculation of an Insulin Sensitivity Index (ISI) 
(25) using the following formula: 
ISI = _10,000_ 
\ [(fasting [glucose] x fasting [insulin]) x (OGTT [glucose] x OGTT [insulin])] 
where [glucose] is expressed in mg/dL, [insulin] is expressed in pU/ml. OGTT [glucose] 
and OGTT [insulin] are the average plasma glucose and insulin concentrations measured 
from t=30 to t=180 during the OGTT. 
The ISI was used to estimate insulin sensitivity instead of the insulin clamp, the 
gold standard for assessing insulin sensitivity, because the latter is too labor intensive to 
be used as a screening tool in large populations. Therefore, data already obtained in the 
lab comparing ISI and the insulin clamp was used to set ISI cut-off values in order to 
identify potentially insulin sensitive and insulin resistant individuals. 
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ISI vs M 
Figure 2. Glucose infusion rate versus insulin sensitivity as assessed by 
the insulin sensitivity index. ISI, insulin sensitivity index; M, glucose 
infusion rate. 
Furthermore, there was an excellent agreement between the ISI and the M-value obtained 
during the euglycemic-hyperinsulinemic clamp (r=0.62) (Figure 2). Based on the 
comparison to the clamp data, insulin resistant offspring (3 males/ll females) were 
defined to have an insulin sensitivity index of less than 4.0, at least one parent or 
grandparent with type 2 diabetes and at least one other family member with type 2 
diabetes. Insulin sensitive control subjects (5 males/7 females) were defined to have an 
insulin sensitivity index greater than 6.3 (with or without a family history of type 2 
diabetes). All qualifying subjects subsequently underwent a complete medical history 
and physical examination. In addition, laboratory blood tests were obtained in order to 
verify normal; blood and platelet count, electrolytes, asparte amino transferase, alanine 
amino transferase, blood urea nitrogen, creatinine, prothrombin time, partial prothrombin 
time, cholesterol and triglycerides. Furthermore, subjects were screened for any metal 

implants, body piercing and claustrophobia and subsequently underwent 'H MRS studies 
to assess liver and muscle triglyceride content, as will be described below. After the 
screening tests, all subjects underwent the euglycemic-hyperinsulinemic clamp study, 
which is the gold standard for assessing insulin sensitivity of liver, muscle and fat, and/or 
!P MRS studies to assess rates of muscle mitochondrial phosphorylation activity. The 
"1P MRS study also allowed us to evaluate muscle fiber type from P,/Pcr in the ’'P 
nuclear magnetic resonance spectrum. Two of the twelve control subjects who were 
initially selected to be insulin sensitive by the ISI from the screening OGTT criteria were 
subsequently excluded after they were found to be insulin resistant by the euglycemic- 
hyperinsulinemic clamp. All subjects in the insulin resistant group were also found to be 
insulin resistant by the insulin clamp. Written consent was obtained from each subject 
after the puipose, nature and potential complications of the studies were explained. The 
protocol was approved by the Yale University Human Investigation Committee. 
Diet and Study Preparation: Subjects were instructed to consume a regular, 
weight maintenance diet containing at least 150 g of carbohydrate per day for three days 
prior to the admission for either the clamp or MRS studies. All subjects were instructed 
not to perform any exercise other than normal walking for the 3 days prior to the study. 
The female subjects were studied during the follicular phase of their menstrual cycle 
(days 0 and 12) in order to minimize changes in ovarian hormonal effects on glucose 
metabolism (26). Subjects who were taking oral contraceptives were studied irrespective 
of their menstrual cycle. Subjects were admitted to the Yale-New Haven Hospital 
General Clinical Research Center the evening before the clamp or 'P MRS study and 
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remained fasting with free access to regular drinking water until the completion of the 
study the following day. 
Metabolites and Hormones: Plasma glucose concentrations were measured 
using a YSI STAT 2700 Analyzer (Yellow Springs, CA). Plasma concentrations of 
insulin, glucagon, adiponectin and resistin were measured using double-antibody 
radioimmunoassay kits (Linco, St. Louis, MO). Plasma concentrations of TNF-a and IL- 
6 were measured by Quantine High Sensitivity kits (R&D Systems, Inc., Minneapolis, 
MN). Plasma fatty acid concentrations were measured using a microfluorometric method 
(27). Urine nitrogen content was measured at the Mayo Medical Laboratories 
(Rochester, MN). Microdialysate glycerol concentrations were measured using an 
enzyme linked colorimetric determination of 0.5 pi samples by a CMA 600 microdialysis 
analyzer (CMA 600 Microdialysis, N. Chelmsford, MA) (28). Ethanol concentrations 
were determined enzymatically using a YSI 2700 STAT Analyzer (YSI, Yellow Springs, 
CA) (28). Gas chromatography mass spectrometer analyses of enrichment of [6,6- 
“H2]glucose and [-H5] glycerol in plasma were performed using a Hewlett-Packard 
5971A Mass Selective Detector (Wilimington, DE) (28). 
Magnetic Resonance Spectroscopic Measurements of Intramyocellular 
and Intrahepatic Triglyceride Content: On a separate day, all subjects were 
transported by a wheelchair to the Yale Magnetic Resonance Center. Localized 'H 
spectra of the soleus muscle were acquired on a 2.1 T Biospec Spectrometer (Bruker 
Instruments, Inc., Billerica, MA) using a coil assembly consisting of two circular 
hydrogen-1 coil loops (13 cm diameter each) arranged spatially to generate a quadrature 
field. During the measurements, the subject remained supine, and the gastrocnemius- 
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soleus complex of the right leg was positioned within the homogeneous volume of the 
magnet. Scout images were acquired in order to position the volume of interest. Volumes 
of interest (15mm x 15mm x 25mm) were centered within the soleus muscle, positioned 
to avoid vascular structures and gross adipose tissue deposits. Localized shimming in the 
soleus was performed using FASTERMAP (29) with typical line widths of ~10 Hz 
obtained. Localized proton spectra were then collected using a PRESS sequence with the 
following parameters: repetition time (Tr) = 3s; echo time (Te) = 21.1ms; 8192 data 
points over 5000 Hz spectral width; 128 scans. Signals in the time domain were 
multiplied by a Gaussian function prior to Fourier transformation and manual phase 
correction. 'H resonances were assigned to water and methyl/methylene of triglycerides 
from their chemical shift, in agreement with Schick et al. (30), and were line fitted using 
the Mac-Nuts-PPC software package (Acorn NMR, Inc., CA, USA). Intramyocellular 
lipid (triglyceride) content (IMCL) and extramyocellular lipid content (EMCL) were 
calculated from the peak areas of intramyocellular CH2 and extramyocellular CH2, 
respectively, with respect to the water peak area, and corrected for T| and T2 relaxation 
effects. The IMCL and EMCL content were then expressed as a percentage of the muscle 
water content (28). 
Similarly, in order to assess the hepatic lipid content localized 'H NMR spectra of 
the liver were obtained using a 12 x 14 cm butterfly ’H observation coil placed rigidly 
over the lateral aspect of the abdomen. Placement of the volume of interest (15mm x 
15mm x 15mm) within the liver was ensured by imaging the liver with a multi-slice 
gradient echo sequence. Prior to each measurement, the H2O signal was optimized using 
a shimming procedure, where lipid signal (predominantly from subcutaneous fat) was 
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suppressed using an inversion recovery method optimized to null the subcutaneous fat 
signal. Localized proton spectra were collected using a modified PRESS sequence with 
the following parameters: TR = 3s; TE = 24.1ms; 8192 data points over 5000 Hz spectral 
width; 64 scans. A saturation slice centered on the chest wall was applied to prevent 
contamination from subcutaneous adipose tissue. The spatial position of the saturation 
slice was determined for each subject from the scout image. A Lorentzian filter of 5Hz 
was applied before Fourier transformation and manual phase correction. Hepatic 
triglyceride content was calculated from the area of intrahepatic CH2 resonance relative 
to the area of the water resonance, using the integration routine of Paravision software 
(Bruker, Billerica, MA), and then expressed as a percentage of liver water content (28). 
Euglycemic-Hyperinsulinemic Clamp Procedure: Basal and insulin stimulated 
rates of glucose and glycerol turnover were assessed during a 3-hour basal period and a 
3-hour euglycemic-hyperinsulinemic (20 mU/m2-min) clamp (Figure 3). In order to 
determine the rates of basal glucose production and glycerol turnover a 3-hour baseline 
infusion was started at 6 a.m. (t=-180 min) with a primed (3.0 mg/kg) continuous (0.05 
mg/kg/min) intravenous infusion of [6,6-“H2]glucose (99% "H enriched) and a continuous 
infusion of [“H5]glycerol (0.03 mg/kg/min, 99% H enriched). During the third hour of 
the baseline infusion a retrograde intravenous catheter was inserted into a hand vein. The 
hand was warmed in a hot box at 55°C for a sampling of arterialized venous blood, which 
was collected from this vein at 10-minute intervals during the last 40 minutes of the basal 
7 
period to measure plasma and insulin concentrations and [6,6-“H2]glucose and 
[2H5]glycerol isotope enrichments. After the blood collection, the basal [6,6-2H2]glucose 
infusion was stopped and the euglycemic-hyperinsulinemic clamp was initiated with a 
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two-step priming dose of insulin (Novolin-R U-100, Novo Nordisk, Princeton, NJ) 
administered as 80 mU/m2-min for 5 minutes followed by 40 mU/irr-min for another 5 
minutes. Insulin was then infused at a continuous rate of 20 mU/m2-min until t=180. The 
plasma glucose concentrations were increased to and maintained at 100±5 mg/dL with a 
variable infusion of glucose (20 g/dL of D-20 enriched to approximately 2.5% with [6,6- 
■y 
“Pbjglucose) (31). Plasma glucose concentrations were measured every 5 minutes and 
the D-20/[6,6-“H2]glucose infusion was adjusted accordingly. Blood was drawn for 
measurements of plasma insulin and glucagon concentrations every 30 minutes 
throughout the clamp. During the last 40 minutes of the clamp period blood was 
collected for the measurement of plasma glucose and insulin concentrations and [6,6- 
•y 7 
"PBJglucose and [“H5]glycerol isotope enrichments in order to determine the glucose and 
glycerol turnover rates (28,31). 
Figure 3. A schematic of the euglycemic- 
hyperinsulinemic clamp, the “gold standard” technique 




Basal glucose production (Ra) was calculated from the infusion rate of the [6,6- 
2H2]glucose and the relative enrichments of the [6,6-2H2]glucose in the infusate (99%) 
and in the plasma: 
Ra= ([6,6-2H2]glucose infusion rate(mg/min)/body weight (kg)) x([APElnf/APEPlasma]-l), 
where APElnf is the [6,6-2H2]glucose infusate Atom Percent Enrichment (99%) and 
APEpiasma is the baseline steady-state plasma [6,6-“H2]glucose Atomic Percent Enrichment 
(%). The term Atomic Percent Enrichment refers to the fraction of isotope of glucose to 
naturally occurring glucose, expressed as a percentage. 
The M-value, the rate of glucose metabolized when plasma glucose 
concentrations were maintained at 100 mg/dL, was calculated as the mean D-20/[6,6- 
2H2]glucose infusion rate over the last 40 minutes of the clamp, corrected for changes in 
plasma glucose concentrations (32). This correction was calculated using the following 
formula: 
Space Correction = [3.795 x surface area (m )/body weight(kg)] x [[glucj]-[glucf]], 
where [glue,] and [glucf] are the initial and final plasma glucose concentrations in mg/dL, 
respectively, during the 40-minutes time interval in which the M-value was calculated. 
The rate of hepatic glucose production during the insulin infusion (Ra) was 
calculated from the following formula: 
Ra= M (mg/kg body weight-min) x ([APEinf/APEP|asma]-l), 
where APEinf is the exogenous D-20/[6,6-“H2]glucose infusate Atom Percent Enrichment 
(which was approximately 2.5%) and APEPiasma is the steady-state clamped plasma [6,6- 
2H2]glucose Atom Percent Enrichment (%). To the extent that the plasma [6,6- 

14 
2H2]glucose enrichment approximates the [6,6-2H2]glucose enrichment in the D-20/[6,6- 
2H2]glucose infusate, hepatic glucose production approximates zero and thus a complete 
suppression of glucose production by insulin is achieved. 
The rate of whole body insulin stimulated glucose disposal (Rd) was calculated 
from the sum of clamped hepatic glucose production (Ra) and the glucose infusion rate 
(M). 
Respiratory exchange measurements: During the last 30 minutes of the 
baseline period and during the last 30 minutes of the clamp, continuous indirect 
calorimetry was performed to measure rates of oxygen and carbon dioxide production 
and of whole body energy expenditure by the ventilated hood technique using the 
Deltatrack Metabolic Monitor (Sensormedics, Anaheim, CA) (33). These measurements 
were then used to calculate glucose and fat oxidation using the following formulas: 
Glucose oxidation: VCL x 0.746 x glucose % of total / body weight (kg) 
and 
Fat oxidation: VCL x 2.029 x fat % of total / body weight (kg), 
where VCF refers to oxygen consumption in ml/min. The non-protein respiratory 
quotients for 100% oxidation of fat and for the oxidation of carbohydrates were 0.707 
and 1.00, respectively, according to the tables of Lusk (34). 
Nonoxidative glucose metabolism, in mg/kg/min, was calculated from the following 
equation: 
Non-oxidative glucose metabolism = M - glucose oxidation, 




Adipose tissue microdialysis: In order to assess in vivo rates of localized 
adipocyte Iipolysis two microdialysis probes (CMA/60, CMA, Microdialysis, Solna, 
Sweden) were inserted into the subcutaneous adipocyte layer on the abdomen, 4-6 cm 
below the umbilicus (28,35), prior to the initiation of the baseline tracer infusions. Saline 
was infused through the outer lumen of the first double lumen microdialysis catheter at a 
rate of 0.3 pl/min. passed through a membrane at the end of the catheter into the 
adipocyte pad and returned via the inner lumen of the catheter (dialysate). This dialysate 
was collected in a vial every 30 minutes throughout the baseline and clamp periods. Once 
steady state was reached, the composition of the dialysate reflected the composition of 
the interstitial fluid in the adipose pad. Subsequently, the concentration of glycerol was 
measured in the dialysate (Figure 4). 
Figure 4. A schematic of the adipocyte microdialysis technique used to 
measure localized glycerol release from the dialysate collected during the final 
30 minutes of the baseline and insulin infusion periods. 
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The percent suppression of glycerol release from the adipocytes was calculated as 
the change in the glycerol concentration in the dialysate between the baseline period and 
the clamp: 
Percent glycerol suppression = GWh- Glyc£ x 100%, 
Glyb 
where Glyb represents the basal serum glycerol concentration and Glyc represents the 
serum glycerol concentration during the clamp. 
Rates of whole-body glycerol turnover (Ra[glyc]) during the basal period and 
during the clamp was calculated from the following formula: 
Ra[glyc]= [2H5]glyc infusion rate (mg/min)/body weight (kg) x 
([APEInf/APEP, asma] 0? 
'y 
where APE]nfis the [“H5]glycerol infusate enrichment (99%) and APEP|asma is the steady- 
state basal plasma [2H5]glycerol enrichment (%). In order to estimate regional adipose 
blood flow, an ethanol-based perfusate was infused at a rate of 2 pl/min through the 
second microdialysis probe. The dialysate was collected, as above, and the ethanol 
recovery rates were calculated as the ratio of ethanol concentration measured in the 
perfusate to the ethanol concentration measured in the dialysate. 
31P Magnetic Resonance Spectroscopy Measurements of Mitochondrial 
Phosphorylation Activity and Muscle Fiber Type Composition: Rates of 
mitochondrial phosphorylation activity were assessed by "'P MRS saturation transfer 
performed at 36.31 MEIz using a flat concentric probe made of a 9-cm diameter inner coil 
(for "'P) and a 13-cm outer coil tuned to proton frequency for scout imaging and 
shimming (36). As described above, the scout image was used to guide the position of 
the volume of interest (~ 1.5 x 2.0 x 6.0 cm3) within the soleus muscle away from major 
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vessels, bone and subcutaneous adipose tissue. Unidirectional rates of adenosine 
triphosphate (ATP) synthesis using the saturation transfer method applied to the 
exchange between Pj and ATP. The steady state Pj magnetization was measured in the 
presence of a selective irradiation of the y resonance of ATP and compared to the 
equilibrium Pj magnetization in a control spectrum (without irradiation of y ATP) (36) 
(Figure 5). That is, the gamma ATP signal in the phosphorous spectrum is saturated and 
the decrease in P; is monitored to assess transfer into ATP. Total acquisition time for P 
spectra was about 120 minutes. 
P,/Pcr in the soleus muscle was measured in the same subjects from the spectrum 
obtained by 11P MRS (37,38), as described above. 
Statistical Analyses: Statistical analyses were performed using the Stat View 
package (Abacus Concepts, Berkeley, CA). To detect statistical differences between 
control and insulin resistant offspring unpaired student t-tests were performed for 
independent samples with a P-value (2-sided) of <0.05 considered significant. Non- 
normally distributed data (i.e. area under the curve data) were log transformed. All data 
are expressed as means ± SEM. 
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Figure 5. !P MRS measurement of yATP synthase flux. The 
top phosphorous spectrum was obtained at equilibrium. 
During the acquisition of the bottom spectrum, the yATP signal 
was saturated and the decrease in Pj was monitored to assess its 
transfer into yATP. ATP, adenosine triphosphate; Pj, inorganic 
phosphate. Po, phosphocreatine. Adapted from (36). 
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Description of Project Involvement: I was involved with subject recruitment 
and study coordination. I helped in the supervision of most of the OGTTs, calculated the 
activity index for each subject and performed many of the insulin assays. I also 
calculated the insulin sensitivity index, which was the basis for the initial allocation of 
subjects into insulin sensitive control subjects and insulin resistant offspring. 
I was present throughout the basal and insulin-stimulated periods of the clamp. 
During the insulin-stimulated component of the euglycemic-hyperinsulinemic clamp, I 
administered the stable isotopes [6,6-“H2]glucose and [~H5]glycerol at the appropriate 
■j 
infusion rates and calculated and adjusted the D-20/[6,6-‘H2]glucose infusion rate every 
five minutes. In addition, I changed the microdialysis catheters every 30 minutes, 
assisted with the collection of blood samples and ensured the comfort of the research 
subjects. 
I performed many of the insulin assays for the euglycemic-hyperinsulinemic 
clamp and calculated the basal hepatic glucose production rates, rates of insulin- 
stimulated whole-body glucose disposal and percent suppression of hepatic glucose 
production. I also calculated the rates of glucose oxidation, non-oxidative glucose 
metabolism and rates of lipid oxidation from the calorimetry data and calculated the basal 
and insulin-stimulated whole body glycerol turnover and percent suppression of whole 
body glycerol release by insulin from the [:H5] glycerol data. Finally, I calculated the 
percent suppression of localized lipolysis from the basal and insulin-stimulated glycerol 
concentrations in the microdialysates. 
My advisor, Kitt Falk Petersen, M.D., oversaw all aspects of the study. Sylvie 
Dufour, Ph.D. and Douglas Befroy, Ph.D. performed the acquisition and the analyses of 
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the ‘HZ'1? magnetic resonance spectroscopic data. Gerald Shulman, M.D., Ph.D. was 




Subject Characteristics: The insulin sensitivity indices for all 200 subjects 
distributed close to normal, with a slight tendency for a leftward shift (Figure 6). 
InaiinSb'Hthitylrriac 
Figure 6. Histogram of the insulin sensitivity index in all subjects 
who underwent the oral glucose tolerance test; N=200. 
Insulin sensitive control and insulin resistant offspring were matched for age, weight, 
height, body mass index, activity index and had similar basal plasma concentrations of 
glycosylated hemoglobin, adiponectin, TNF- a, IL-6 and resistin (Table 1). In contrast, 
the insulin sensitivity index was markedly lower in the insulin resistant offspring 







Age (years) 28±7 26±7 
Weight (kg) 60±13 64±9 
Height (m) 1.69±0.11 1.65±0.09 
Body Mass Index (kg/m2) 21 ±2 23±2 
Activity Index 2.6±0.5 2.4±0.4 
Glycosylated Hemoglobin (%) 5.1 ±0.3 5.2±0.4 
Adiponectin (pg/ml) 12±4 11±4 
TNF-a (pg/ml) 1.5±0.3 1.8±0.9 
IL-6 (pg/ml) 0.52±0.31 0.68±0.42 
Resistin (ng/ml) 0.77±0.24 0.79±0.24 
Table 1. Subject characteristics and fasting plasma concentrations of 
glycosylatedhemoglobin and adipocyte derived factors in insulin sensitive 
control and insulin resistant offspring. TNF-a, tumor necrosis factor-a; IL-6, 
interleukin-6. Data are ± SEM. 
Oral Glucose Tolerance Test: All subjects had normal glucose tolerance (fasting plasma 
glucose <110 mg/dL, 2-hour postload glucose <140 mg/dL), as determined by the 
OGTT, but the plasma glucose (Figure 7a) and insulin (Figure 7b) concentrations before 
and during the test were significantly higher in the insulin resistant offspring. Basal 
plasma fatty acid concentrations were similar in the insulin sensitive control (0.37±0,05 
mM) and insulin resistant offspring (0.47±0.05 mM, P=0.17) and decreased by 
approximately 80% in both groups during the glucose tolerance test (Figure 7c). There 
were no differences in the basal plasma glucagon concentrations in the insulin sensitive 
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Figure 7. Plasma concentrations of: (a) glucose*, (b) insulin’ (c) 
free fatty acids before and during an oral glucose tolerance test in 
insulin sensitive control (n=9) and insulin resistant offspring (n=14). 
(P=0.016 for area under the curve for glucose concentration between 
insulin sensitive controls and insulin resistant offspring; P=0.002 for 
area under the curve for insulin concentration between control and 
insulin resistant offspring). *To convert glucose values to millimole 
per liter, divide by 18, |To convert insulin values to pmole per liter 
multiply by 6.0. 
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Eiiglycemic-Hyperinsulinemic Clamps: Basal rates of glucose production were 
similar in the insulin sensitive control subjects (2.3±0.1 mg/kg/min, N=9) and insulin 
resistant offspring subjects (2.0±0.3 mg/kg/min, N=8, p=0.41) and suppressed completely 
in both groups during the euglycemic-hyperinsulinemic clamp. In contrast, rates of 
glucose infusion required to maintain euglycemia (control: 7.7±0.5 mg/kg/min and 
insulin resistant offspring: 3.3±0.3 mg/kg/min, PcO.OOl) and insulin stimulated rates of 
peripheral glucose uptake were approximately 60% lower in the insulin resistant 
offspring subjects compared to the insulin sensitive control subjects during the clamp 
(Figure 8). This reduction in peripheral glucose metabolism could mostly be attributed to 
an approximately 70% reduction (PcO.OOl) in nonoxidative glucose disposal in the 
insulin resistant offspring (Figure 8). 
Figure 8. Rates of insulin stimulated glucose metabolism were lower in 
the insulin resistant (IR) offspring (N=8), which could be attributed to an 
approximately 70% reduction in non-oxidative glucose disposal in this 
group, compared to insulin sensitive control subjects (N=9). 
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There were no differences between the two groups in basal or insulin stimulated rates of: 
glucose oxidation [(Basal; control: 0.8±0.2 mg/kg/min, insulin resistant offspring: 
0.9±0.2 mg/kg/min, P=0.76), (Insulin Stimulated; control: 1.8.±0.2 mg/kg/min, insulin 
resistant offspring: 1.3±0.2 mg/kg/min, P=0.12)], rates of whole body lipid oxidation 
[(Basal; control: 4.2±0.9 mg/kg/min, insulin resistant offspring: 3.0±0.6 mg/kg/min, 
P=0.32), (Insulin Stimulated; control: 1.3±0.5 mg/kg/min, insulin resistant offspring: 
2.0±0.6 mg/kg/min, P=0.36)], or respiratory quotient (rates of oxygen uptake/rates of 
carbon dioxide production, in ml/min) [(Basal; control: 0.81±0.02, insulin resistant 
offspring: 0.82±0.02, P=0.80), (Insulin Stimulated; control: 0.91±0.02, insulin resistant 
offspring: 0.87±0.02, P=0.21). Basal (control: 24.6±1.1 kcal/kg/24h, insulin resistant 
offspring: 21.8±0.7 kcal/kg/24h, P=0.06) and insulin stimulated (control: 24.9±0.7 
kcal/kg/24h, insulin resistant offspring: 21.6±0.9 kcal/kg/24h, P=0.01) rates of whole 
body energy expenditure tended to be lower in the insulin resistant offspring. 
Whole Body and Localized Rates of Glycerol Metabolism: Basal rates of whole 
body glycerol turnover (control: 0.21±0.03 pmol/min, insulin resistant offspring: 
0.18±0.02 pmol/min, P=0.32) and insulin suppression of glycerol turnover during the 
clamp (control: 0.11 ±0.01 pmol/min, insulin resistant offspring: 0.09±0.01 pmol/min, 
P=0.32) were similar in the control and insulin resistant offspring (Figure 9). 
Consistent with this finding the interstitial glycerol concentrations, assessed by 
microdialysis, decreased by a similar degree in the insulin sensitive control subjects 
(36±7%) and insulin resistant offspring (41±6%, P=0.67) during the euglycemic- 
hyperinsulinemic clamp (Figure 10). 
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Figure 9. Rates of whole body glycerol turnover were not significantly 
different between the insulin resistant (IR) offspring and insulin 
sensitive control subjects at baseline and suppressed comparably during 
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Figure 10. There was no significant difference in the ability of insulin to 
suppress local glycerol release from adipocytes, as measured by 
microdialysis, between the insulin resistant (IR) offspring and insulin 
sensitive control subjects. 
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77 Magnetic Resonance Spectroscopy assessment of Iiitramyo cellular and Intrahepatic 
Triglyceride Content: The intramyocellular lipid content in the soleus muscle, as 
determined by 'H MRS, was increased by approximately 80% (P=0.005) in the insulin 
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Figure 11. Intramyocellular lipid content was approximately 80% higher 
in the insulin resistant offspring, as compared to the control subjects. 
There was a tendency, although not significant, for the intrahepatic triglyceride 
content to be higher in the insulin resistant offspring (2.35± 1.49 percent) compared to the 
insulin sensitive control subjects (0.47±0.16 percent, P=0.29). 
P Magnetic Resonance Spectroscopy Assessment of Mitochondrial 
Phosphorylation Activity and Muscle Tiber Type Composition: Rales of mitochondrial 
phosphorylation activity in skeletal muscle were approximately 30 percent lower 
(P=0.01) in the insulin resistant offspring (N=13) compared to the insulin sensitive 
control subjects (N=10) (Figure 12). 

9 n 
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Figure 12. Rates of muscle mitochondrial phosphorylation activity in 
skeletal muscle of were approximately 30% lower in insulin resistant (IR) 
offspring, as compared to insulin sensitive control subjects. 
The ratio of type 1/type II fiber type composition of the soleus muscle, as reflected 
by Pj/Pa, was reduced by approximately 20 percent (P=0.002) in the insulin resistant 




In this study, we examined the mechanism of insulin resistance in lean insulin 
resistant offspring of type 2 diabetic patients, compared to age-height-weight-activity 
matched insulin sensitive control subjects. Specifically, we examined two possible 
hypotheses that could account for the accumulation of intramyocellular lipids and thus 
insulin resistance in our study population: 1) increased fatty acid delivery to the muscle 
cells secondary to defects in lipolysis and 2) decreased fatty acid oxidation secondary to 
defects in mitochondrial oxidative-phosphorylation activity in the muscle. 
As expected, we found that the insulin resistant offspring were severely insulin 
resistant, compared to the insulin sensitive control subjects, and that this could mostly be 
attributed to an approximately 70 percent reduction in insulin stimulated non-oxidative 
muscle glucose metabolism. As expected, using 'H MRS to measure intramyocellular 
lipid content we found that insulin resistance in muscle was accompanied by an 
approximately 80 percent increase in intramyocellular lipid content in the insulin resistant 
offspring compared to insulin sensitive control subjects. These data are consistent with 
previous studies in man (8-10) and rodents (39, 40) that have suggested an important role 
of dysregulated intramuscular fatty acid metabolism in causing insulin resistance and 
supports a similar role for fat induced insulin resistance in skeletal muscle of insulin 
resistant offspring. 
In order to examine whether the increase in intramyocellular lipid content in the 
insulin resistant offspring was due to increased delivery of fatty acids to the muscle we 
measured whole body and localized rates of lipolysis. Rates of whole body lipolysis were 
similar in the control and insulin resistant offspring during the basal state and suppressed 
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equally during the euglycemic-hyperinsulinemic clamp. Consistent with this finding we 
found that insulin suppression of localized rates of hpolysis in subcutaneous fat, assessed 
by microdialysis, was also similar in both groups. Taken together these data suggest that 
insulin resistance was confined mostly to skeletal muscle and that increased basal rates of 
peripheral lipolysis, and/or defects in insulin suppression of lipolysis, do not play a major 
role in causing the increased intramyocellular lipid content observed in the insulin 
resistant offspring. 
In order to assess whether decreased mitochondrial activity might be a 
contributing factor to the increased intramyocellular lipid content we also assessed rates 
of muscle mitochondrial phosphorylation activity in vivo by 'P MRS. Using this 
procedure we found that rates of mitochondrial ATP production were reduced by 
approximately 30 percent in muscle of the insulin resistant offspring compared to the 
insulin sensitive control subjects. One possible explanation for this finding might be a 
lower ratio of type I fibers (mostly oxidative) to type II fibers (mostly glycolytic) in the 
insulin resistant offspring. In order to test this possibility we also performed 'P MRS 
measurements to noninvasively assess the relative Pj/PCr, which has been shown to be an 
excellent indicator of the relative ratio of type I to type II muscle fibers (37, 38), and 
found that the insulin resistant offspring had a approximately 20 percent reduction in the 
ratio of type I to type II muscle fiber types. This finding is consistent with a biopsy study 
by Nyholm et al. in which an increased number of type lib muscle fibers was found in 
overweight insulin resistant first degree relatives of patients with type 2 diabetes (41). 
Taken together these data suggest that insulin resistant offspring have an inherited 
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reduction in mitochondrial content in muscle, which in turn may be responsible for the 
reduced rates of mitochondrial oxidative-phosphorylation activity. 
Several recent studies have also implicated several novel adipocyte derived 
factors in mediating insulin resistance in obesity and type 2 diabetes (20, 21, 41-45). In 
order to address the potential role of resistin, TNF-a, IL-6 and adiponectin in mediating 
insulin resistance in the insulin resistant offspring we measured the plasma 
concentrations of these factors and found no differences between the two groups. These 
data suggest that alterations in plasma concentrations of these adipocyte-derived factors 
do not have a major role in mediating insulin resistance in insulin resistant offspring. 
In summary, to our knowledge, these are the first studies to assess systemic and 
localized rates of lipolysis, adipocyte derived factors, mitochondrial phosphorylation 
activity and fiber type in muscle of healthy young, lean, normoglycemic insulin resistant 
offspring. Taken together these results support the hypothesis that insulin resistance in 
the insulin resistant offspring is due to dysregulation of intramyocellular fatty acid 
metabolism which may be caused by an inherited defect in mitochondrial oxidative- 
phosphorylation activity, which in turn may be attributed to a reduced ratio of type I/type 
II muscle fiber types. These results are similar to those observed in insulin resistant lean 
elderly subjects which, in contrast, are likely attributable to acquired defects in 
mitochondrial biogenesis leading to reduced skeletal muscle mitochondrial content (46) 
(Figure 13). Furthermore since mitochondria play a critical role in mediating glucose 
induced insulin secretion (47) similar inherited defects in beta cell mitochondrial 
function/content, in the setting of peripheral insulin resistance, might explain the very 
high incidence of diabetes in these individuals (6). 
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In this regard it is of interest that a common Gly482Ser polymorphism of 
peroxisome proliferator-activated receptor y coactivator-1, a transcriptional regulator of 
genes responsible for mitochondrial biogenesis and fat oxidation (48), has been linked to 
an increased relative risk for type 2 diabetes in Danish (49) populations as well as altered 
lipid oxidation and insulin secretion in Pima Indians (50). These data also identify 
mitochondria! oxidative-phosphorylation activity as a potential novel therapeutic target 
for prevention and treatment of type 2 diabetes. Additionally, two very recent DNA 
microarray analysis studies suggest that a coordinated reduction of PGC-la genes 
involved in oxidative phosphorylation occurs in skeletal muscle of overweight patients 
with type 2 diabetes (51) and in obese Mexican-Americans with type 2 diabetes and 
overweight family history-positive non-diabetic subjects (52). 
Future studies in our laboratory will address the question of whether a decrease in 
intramyocellular lipid content through a small weight loss will lead to an improvement in 
insulin sensitivity in normal weight insulin resistant offspring of type 2 diabetics. 
Another study will examine the number of mitochondria in the muscle of these offspring 
to assess whether a decrease in mitochondrial number could account for the decreased 
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Figure 13. Proposed mechanism for the development of insulin resistance in insulin 
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